ANAPTYSBIO, INC (ANAB) FY2025 10-K Annual Report
ANAPTYSBIO, INC (ANAB) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 3, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ANAPTYSBIO, INC FY2025 10-K Analysis
Business Overview
- • Business model: Biopharma company focusing on clinical development and commercialization collaborations, recognizing revenue mainly from milestones and royalties, not product sales
- • New monetization deals in 2024: Sold additional Jemperli royalty receivables for $50M, expanding prior $250M monetization agreement with Sagard
Risk Factors
- • FDA acceptance of Vanda's imsidolimab BLA for GPP with target action date December 12, 2026, creating regulatory milestone risk
- • Exposure to global macroeconomic shifts impacting 424-patient rosnilimab Phase 2b RA trial conducted worldwide
ANAPTYSBIO, INC FY2025 Key Financial MetricsXBRL
Revenue
$235M
▲ +157.0% YoY
Net Income
-$13M
▲ +90.9% YoY
Operating Margin
20.4%
▲ +14635bp YoY
Net Margin
-5.6%
▲ +15346bp YoY
ROE
-35.6%
▲ +16937bp YoY
Total Assets
$364M
▼ -24.7% YoY
EPS (Diluted)
$-0.46
▲ +91.0% YoY
Operating Cash Flow
$20M
▲ +114.6% YoY
Source: XBRL data from ANAPTYSBIO, INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ANAPTYSBIO, INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.